Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

IMA new masthead1

July 30, 2009

View Archives Issues

  • New Gender and Age-specific USPSTF Aspirin Recommendations

    Aspirin reduces the risk for myocardial infarction in men ages 45-79 and for stroke in women ages 55-79; however, its use must be balanced against the increased risk of serious bleeding events in each individual patient.
  • CT Colonography: Is It a Good Option?

    CT colonography is a screening tool that appears to be reasonably good at identifying colorectal cancer in asymptomatic patients at increased risk for colorectal cancer when compared to colonoscopy. Increased risk is defined as those with a family history of advanced neoplasia in first-degree relatives, personal history of colorectal adenomas, or positive results from fecal occult blood tests (FOBTs).
  • Cardiovascular Risks of NSAIDs

    When using an NSAID, a physician must weigh the anticipated therapeutic benefits and assess the potential risks from both the cardiovascular and gastrointestinal perspectives, and the final therapeutic decision should be individualized.
  • The Power of Groups in Managing Diabetes

    Group visits of diabetic patients have the power to foster lifestyle change, improve the control of diabetes and related cardiovascular risk factors, and lower health care costs.
  • Bromocriptine Mesylate Tablets (Cycloset™)

    Bromocriptine, a dopamine receptor agonist initially approved in 1978 as Parlodel®, has been approved for the treating type 2 diabetes mellitus. The drug is marketed as a quick release formulation by VeroScience LLC as Cycloset™.
  • Clinical Briefs by Louis Kuritzky, MD

    Aspirin reduces the risk for myocardial infarction in men ages 45-79 and for stroke in women ages 55-79; however, its use must be balanced against the increased risk of serious bleeding events in each individual patient.